Original Vitamin C information

[Guest guest]

Ricky,

Here is my original paper after reading the entire French report - this

is in lay persons terms.

http://www.cmtworld.org/epublisher/publish/article_00103.php If you

want the medical report here's the abstract below from April 2004 Nature

Medicine. To get the entire text, you will be charged a fee by Nature

Medicine. Also, had some research she found - you can find all of

this in our archives starting towards the end of March 2004. ~ Gretchen

" Ascorbic acid treatment corrects the phenotype of a mouse model of

Charcot-Marie-Tooth disease.

Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce V, Pizant J,

Thirion X, Robaglia-Schlupp A, Pellissier JF, Fontes M.

Institut National de la Sante et de la Recherche Medicale UMR491, IPHM,

Faculte de Medecine de la Timone, 27 Bd. J. Moulin, 13385 Marseille

Cedex 5, France.

Charcot-Marie-Tooth disease (CMT) is the most common hereditary

peripheral neuropathy, affecting 1 in 2,500 people. The only treatment

currently available is rehabilitation or corrective surgery. The most

frequent form of the disease, CMT-1A, involves abnormal myelination of

the peripheral nerves. Here we used a mouse model of CMT-1A to test the

ability of ascorbic acid, a known promoter of myelination, to correct

the CMT-1A phenotype. Ascorbic acid treatment resulted in substantial

amelioration of the CMT-1A phenotype, and reduced the expression of

PMP22 to a level below what is necessary to induce the disease

phenotype. As ascorbic acid has already been approved by the FDA for

other clinical indications, it offers an immediate therapeutic

possibility for patients with the disease.